- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 04.05. | Day One Biopharmaceuticals, Inc. - 15-12G, Securities registration termination | - | SEC Filings | ||
| 23.04. | Servier Acquires Day One Biopharmaceuticals | 9 | Contract Pharma | ||
| 23.04. | Servier completes the acquisition of Day One Biopharmaceuticals | 588 | PR Newswire | Acquisition expands Servier's position in oncology with tovorafenib marketed as OJEMDATM in the U.S. in pediatric low-grade glioma. Transaction also includes a strong oncology pipeline of... ► Artikel lesen | |
| 23.04. | NSE - Day One Biopharmaceuticals, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | 1 | SEC Filings | ||
| 23.04. | Day One Biopharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.04. | Day One Biopharmaceuticals, Inc. - 10-K/A, Annual Report | - | SEC Filings | ||
| 13.03. | Weekly Buzz: Bristol Myers Squibb Wins FDA Nod; EU Okays Johnson & Johnson's AKEEGA; Ipsen Withdraws Tazverik, Day One Biopharmaceuticals Acquired | 3.494 | AFX News | NEW BRUNSWICK (dpa-AFX) - This week's biotech landscape witnessed key FDA approvals, EU approvals, IND clearances, acquisitions, and clinical trial data readouts across key therapeutic areas... ► Artikel lesen | |
| DAY ONE BIOPHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 11.03. | JPMorgan downgrades Day One Biopharmaceuticals stock rating on Servier acquisition | 6 | Investing.com | ||
| 10.03. | This Day One Biopharmaceuticals Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday | 2 | Benzinga.com | ||
| 09.03. | Servier acquires International Biotech's Day One Biopharmaceuticals for USD2.5 billion | 3 | Alliance News | ||
| 09.03. | Intnl. Biotechnology - Portfolio company Day One Biopharmaceuticals acquired by Servier | 1 | RNS | ||
| 07.03. | Key deals this week: Diana Shipping, Day One BioPharmaceuticals, Hudbay Minerals and more | 24 | Seeking Alpha | ||
| 07.03. | Day One Biopharmaceuticals (DAWN) Climbs to 3-Year High on $2.5-Billion Merger | 1 | Insider Monkey | ||
| 06.03. | Servier Boosts Presence in Rare Cancers With $2.5B Acquisition of Day One Biopharma | 13 | MedCity News | ||
| 06.03. | Servier Acquiring Day One Biopharmaceuticals For About $2.5 Billion | 1 | pulse2.com | ||
| 06.03. | Servier Acquires Day One Biopharmaceuticals, Expanding Rare Oncology Portfolio | 2 | Contract Pharma | ||
| 06.03. | Servier to build cancer drug pipeline with $2.5B purchase of Day One Biopharmaceuticals | 1 | BioPharma Dive | ||
| 06.03. | TD Cowen downgrades Day One Biopharmaceuticals stock on Servier deal | 3 | Investing.com | ||
| 06.03. | Oppenheimer reiterates Day One Biopharmaceuticals stock rating on Servier deal | 2 | Investing.com | ||
| 06.03. | Jones Trading cuts Day One Biopharmaceuticals stock rating on Servier acquisition | 1 | Investing.com |
1 2 Weiter >>
40 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 80,15 | -1,35 % | Chancen & Risiken bei den Q.2-Kennzahlen - Almonty Industries, BioNTech, Danaher, Pfizer, Sartorius | Die globalen Aktienmärkte bleiben dynamisch, und die fundamentalen Rahmenbedingungen haben sich in den letzten Quartalen rasant verändert. Im heutigen Bericht analysieren wir drei faszinierende Unternehmen... ► Artikel lesen | |
| AMGEN | 334,55 | -1,23 % | Kleinzelliges Lungenkarzinom (SCLC): Hoch aggressiv und schwer behandelbar / Biotechnologieunternehmen Amgen engagiert sich in der Erforschung neuer Therapieansätze | München (ots) - Das kleinzellige Lungenkarzinom (Small Cell Lung Cancer, SCLC) ist eine der aggressivsten Formen von Lungenkrebs. Die Erkrankung schreitet besonders schnell voran, streut früh in andere... ► Artikel lesen | |
| NOVAVAX | 6,460 | +0,78 % | Novavax, Inc.: Novavax Reports First Quarter 2026 Financial Results and Operational Highlights | Total revenue of $140 million in the first quarter of 2026
Pfizer agreement announced in January for non-exclusive license to utilize Matrix-M® in two infectious... ► Artikel lesen | |
| BIOGEN | 176,76 | -3,35 % | Ihre wichtigsten Termine: Heute im Fokus: Meta, Microsoft, Qualcomm, Biogen, Airbus, Porsche und L' Oréal | © Foto: Andrej Sokolow/dpaGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Untermehmenstermine 06:30... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 41,740 | +0,34 % | Morningstar, Inc.: Morningstar Completes Rebrand of CRSP Market Indexes to Morningstar Market Indexes | Indexes underpinning more than $3 trillion in investor assets move under the Morningstar brand, expanding visibility and supporting future growth
Morningstar, Inc. (NASDAQ: MORN), a leading provider... ► Artikel lesen | |
| VIKING THERAPEUTICS | 27,800 | -4,96 % | Viking Therapeutics, Inc.: Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Conference call scheduled for 4:30 p.m. ET today
-- Phase 3 VANQUISH 1 & 2 Trials for Subcutaneous VK2735 in Obesity Fully Enrolled and Advancing --
-- Oral Phase... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 9,500 | +0,53 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema | Data from HAELO Phase 3 clinical trial presented today in a late-breaking oral session at European Academy of Allergy & Clinical Immunology Annual Congress 2026HAELO manuscript simultaneously published... ► Artikel lesen | |
| TEMPUS AI | 37,585 | +3,51 % | Opening Bell: SpaceX, Tesla, Alphabet, NextEra, Intel, Tempus AI | An der Wall Street haben die Verkäufer am Donnerstag das Geschehen dominiert. Der Dow Jones gab bis zum Handelsende um 0,97 Prozent nach. Bereits zum Auftakt hatte der Leitindex klar im Minus gelegen... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 8,028 | -3,53 % | BioCryst Pharmaceuticals Appoints David Jenkins As Chief Scientific Officer | PARIS (dpa-AFX) - BioCryst Pharmaceuticals, Inc. (BCRX) said on Wednesday that it has appointed David W. Jenkins to the newly created role of Chief Scientific Officer with immediate effect.In... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 53,70 | -1,03 % | H.C. Wainwright reiterates BioMarin stock rating at Neutral | ||
| EXELIXIS | 47,985 | -0,74 % | Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report? | ||
| SAREPTA THERAPEUTICS | 13,360 | -1,62 % | Sarepta Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,235 | +0,57 % | Pacific Biosciences of California (PACB) Laps the Stock Market: Here's Why | ||
| CARDIOL THERAPEUTICS | 1,022 | +1,39 % | Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): Buy | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH
20.07.2026 / 16:41 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The... ► Artikel lesen | |
| VAXART | 0,600 | 0,00 % | Vaxart, Inc. - 8-K, Current Report |
DAY ONE BIOPHARMACEUTICALS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 21,530 Euro und damit 0,00 % im Plus.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DAY ONE BIOPHARMACEUTICALS INC finden Sie auf Wallstreet Online.